X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
R327 (RECCE-327) is a fast-acting anti-infective effective against Gram-positive & negative bacteria, including resistant forms. It is under development for the treatment of Urinary tract infections.
Lead Product(s): R327
Therapeutic Area: Infections and Infectious Diseases Product Name: RECCE 327
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 01, 2024
Details:
R327 (RECCE-327) is a fast-acting anti-infective effective against Gram-positive & negative bacteria. It is under development for the treatment of acute bacterial skin and skin structure infections.
Lead Product(s): R327
Therapeutic Area: Podiatry Product Name: Recce 327
Highest Development Status: Phase I/ Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 25, 2024
Details:
R327 (RECCE-327) is a fast-acting, broad-spectrum anti-infective effective against Gram-positive and Gram-negative bacteria. It is under development for the treatment of Urinary tract infections.
Lead Product(s): R327
Therapeutic Area: Infections and Infectious Diseases Product Name: Recce 327
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 12, 2024
Details:
R327 (RECCE-327) is a broad-spectrum anti-infective effective against Gram-positive and Gram-negative bacteria, including their resistant forms. It is under development for Urinary tract infections.
Lead Product(s): R327
Therapeutic Area: Infections and Infectious Diseases Product Name: Recce 327
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 17, 2024
Details:
R327 (RECCE-327) is a fast-acting, broad-spectrum anti-infective effective against Gram-positive and Gram-negative bacteria, including their resistant forms. It is under development for the treatment of lung infections.
Lead Product(s): R327
Therapeutic Area: Infections and Infectious Diseases Product Name: Recce 327
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable May 13, 2024
Details:
R327 (RECCE-327) is a fast-acting, broad-spectrum anti-infective effective against Gram-positive and Gram-negative bacteria, including their resistant forms. It is under development for the treatment of Urinary tract infections.
Lead Product(s): R327
Therapeutic Area: Infections and Infectious Diseases Product Name: RECCE 327
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 30, 2024
Details:
RECCE 327 (R327) is a rapid and irreversible bactericidal against gram-negative escherichia coli (E. coli) bacteria, in both active and stationary phase cells, which is being investigated as a treatment for sepsis and complicated/uncomplicated urinary tract infections.
Lead Product(s): R327
Therapeutic Area: Infections and Infectious Diseases Product Name: RECCE 327
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 19, 2024
Details:
RECCE 327 (R327) is a rapid and irreversible bactericidal against gram-negative escherichia coli (E. coli) bacteria, in both active and stationary phase cells, which is being investigated as a treatment for sepsis and complicated/uncomplicated urinary tract infections.
Lead Product(s): R327
Therapeutic Area: Infections and Infectious Diseases Product Name: RECCE 327
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 14, 2024
Details:
The collaboration aims to focus on the clinical advancement of RECCE 327 (R327). Currently it is being evaluated in the clinical trial studies for the treatment of Urinary tract infections including urosepsis.
Lead Product(s): R327
Therapeutic Area: Infections and Infectious Diseases Product Name: RECCE 327
Highest Development Status: IND EnablingProduct Type: Small molecule
Partner/Sponsor/Collaborator: Murdoch Children’s Research Institute
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership February 29, 2024
Details:
RECCE 327 (R327) is a novel topical Bacterial ATP production inhibitor which is under phase 1/2 clinical development for the treatment of Diabetic Foot Infections.
Lead Product(s): R327
Therapeutic Area: Podiatry Product Name: RECCE 327
Highest Development Status: Phase IIProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable February 27, 2024
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
